コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 fficiently in the presence of the CD70-fiber bispecific antibody.
2 ed in the same cell to assemble a functional bispecific antibody.
3 Using this approach, we produce 28 unique bispecific antibodies.
4 d in the same cell to generate heterodimeric bispecific antibodies.
5 ction provides a novel synthetic approach to bispecific antibodies.
6 small-scale generation of human full-length bispecific antibodies.
7 armacophores to generate optimized or unique bispecific antibodies.
8 ltaneous targeting of two tumor targets with bispecific antibodies.
9 and improved sources of clinically relevant bispecific antibodies.
10 ery with possible functional implications in bispecific antibodies.
11 tent antibodies and explore the potential of bispecific antibodies.
15 nd, we produced a recombinant human IgG-like bispecific antibody, a Di-diabody, using the variable re
21 Here, we describe the synthesis of a novel bispecific antibody, alphaCLL1-alphaCD3, using the genet
22 mune activation of cytotoxic effector cells, bispecific antibodies and antibodies linked to superanti
26 These results support this new approach to bispecific antibodies and offer a potential new strategy
27 successfully redirected to tumor cells using bispecific antibodies and offer a promising strategy for
29 rved following administration of natural and bispecific antibodies and, more recently, following adop
30 ased on a glycoprotein A33 (GPA33)-targeting bispecific antibody and a small-molecule radioactive hap
32 Psl, and susceptibility to the anti-PcrV/Psl bispecific antibody and clinical candidate MEDI3902.
34 Fc containing therapeutics (e.g. antibodies, bispecific antibodies, and Fc fusions) requiring lack of
35 , leading to the formation of monovalent but bispecific antibodies, and it interacts poorly with Fcga
36 position of the blood-brain barrier-crossing bispecific antibody antagonist of metabotropic glutamate
37 ess in research on intracellular antibodies, bispecific antibodies, antibody-fusion molecules, and an
38 otein-coupled receptors using a BBB-crossing bispecific antibody approach and emerging principles tha
44 ignaling pathways were evaluated during EGFR bispecific antibody armed ATC (aATC)-mediated killing of
46 payloads such as other antibodies to create bispecific antibodies as well as organic and non-organic
47 nity Re-Targeting (DART) proteins, which are bispecific, antibody-based molecules that can bind 2 dis
51 o 20-fold more potently than a CS1-targeting bispecific antibody (BiFab-CS1) developed in an analogou
52 this approach to the development of chimeric bispecific antibody binding site (chi BABS) proteins.
53 e used antibody engineering to develop novel bispecific antibodies (Bis-mAbs) that are cross-reactive
55 ltaneous engagement of two distinct targets, bispecific antibodies broaden the potential utility of a
56 We previously described a highly flexible bispecific antibody (bs-mAb) pretargeting procedure usin
57 ied using PrA-MS and are presented here: (a) bispecific antibodies (bsAb) and (b) glycan engineered a
58 Methods to rapidly generate high quality bispecific antibodies (BsAb) having normal half-lives ar
59 nical studies to date have demonstrated that bispecific antibodies (BsAb) may have potentially signif
62 ted and produced two fully human recombinant bispecific antibodies (BsAb) that target both EGFR and I
63 ectively targeted against malignant B cells, bispecific antibodies (BsAb) were constructed from two a
64 s such as antibody-drug conjugates (ADC) and bispecific antibodies (bsAb), are the fastest growing cl
65 d DNL to generate a novel class of trivalent bispecific antibodies (bsAb), each comprising an anti-CD
67 ived macrophages mediated by MAb DF3 and its bispecific antibody (BsAb) DF3xH22 with the second epito
69 inical evaluation of a recombinant AC133xCD3 bispecific antibody (bsAb) that redirects human polyclon
71 These deficiencies were overcome by using a bispecific antibody (bsAb) with specificities for human
78 a pair of humanized hexavalent anti-CD20/22 bispecific antibodies (bsAbs) derived from veltuzumab (v
80 Many methods have been developed to produce bispecific antibodies (BsAbs) for industrial application
81 cacy of engaging multiple drug targets using bispecific antibodies (BsAbs) is affected by the relativ
82 g T cells to hematological malignancies with bispecific antibodies (BsAbs) is an attractive strategy.
88 onal mouse anti-TnI IgG mAb 265, (2) TnI and bispecific antibodies (BsAbs) which on one end recognize
89 This results in functionally monovalent, bispecific antibodies (bsAbs) with unknown specificity a
91 chimeric anticarcinoembryonic antigen (CEA) bispecific antibody (BsMAb) and peptides labeled with (1
92 ing method using a new recombinant anti-CD20 bispecific antibody (bsMAb) followed by (90)Y-1,4,7,10-t
96 rm of generating bispecific IgG antibodies, "Bispecific Antibody by Protein Trans-splicing (BAPTS)".
97 e, we review the principle of a new class of bispecific antibodies called BiTE (for "bispecific T-cel
100 us, Ad) vectors targeted to CD40 by means of bispecific antibodies can enhance gene transfer to murin
101 These results indicate that the CD70-fiber bispecific antibody can enhance rAd infection of CD70-po
102 he two parental antibodies and that a single bispecific antibody can neutralize 97% of viral strains
105 egies predicated on streptavidin and biotin, bispecific antibodies, complementary oligonucleotides, a
106 act specifically with the capture arm of the bispecific antibody complex were used to demonstrate the
109 vel, potently neutralizing, tetravalent, and bispecific antibody composed of 2 heavy-chain-only VH (V
110 nsfer specifically to tumor cells, we used a bispecific antibody conjugate to ablate Ad binding to fi
112 n leukemic cytotoxic T cells triggered via a bispecific antibody containing an anti-CD3 F(ab') to kil
113 l trials have been initiated to test whether bispecific antibodies could redirect immune effectors ag
116 d a DropArray cell-based assay to evaluate a bispecific antibody designed to engage cytotoxic T cells
120 nded the technology by developing a two-part bispecific antibody discovery strategy that facilitates
125 tional monoclonal antibodies, knob-into-hole bispecific antibodies face unique challenges in producti
126 experiments revealed that high-affinity TfR bispecific antibodies facilitated the trafficking of TfR
127 To counter this problem, we developed a bispecific antibody (FIT-1) comprising ZKA190 and a seco
130 h the identification of a common light chain bispecific antibody for large-scale production with high
131 adionuclides, a new anti-Trop-2 x antihapten bispecific antibody for pretargeting, based on humanized
132 While the clinical potential for certain bispecific antibody formats is clear, progress has been
133 en hindered by the difficulty of identifying bispecific antibody formats that exhibit favorable pharm
136 the construction of other disease-targeting bispecific antibody fragments for early detection and di
137 provides a versatile platform for generating bispecific antibody fragments for redirected killing and
138 Our strategy allows rapid generation of bispecific antibodies from any two existing antibodies a
139 increasing number of multivalent antibodies, bispecific antibodies, fusion proteins, and targeted nan
145 orm conventional monoclonal antibodies, many bispecific antibodies have issues regarding production,
148 nerality of the approach and show that these bispecific antibodies have properties similar to those o
150 eting" methods, particularly those utilizing bispecific antibodies, have greatly enhanced the therape
152 this study, we describe a trastuzumab-based bispecific antibody, HER2-TDB, which targets HER2 and co
153 ti-diethylenetriaminepentaacetic acid (DTPA) bispecific antibody (hMN-14 x m734) (40 mg/m(2)), follow
155 i-CD30 antibodies as well as anti-CD30-based bispecific antibodies, immunotoxins, and radioimmunoconj
160 g, this mechanism leads to the production of bispecific antibodies in which the LAIR1 domain is preci
163 in advance of the radiolabeled veltuzumab or bispecific antibody injection, tumor uptake was signific
164 T-cell-directed killing of tumor cells using bispecific antibodies is a promising approach for the tr
167 s of the efficient small-scale generation of bispecific antibodies lacking a common light chain and t
168 , semisynthetic method for the production of bispecific antibody-like therapeutics in which a derivat
169 Using the DEKK format, we generated the bispecific antibody MCLA-128, targeting human EGF recept
171 totoxic potential, however, was restored via bispecific antibody-mediated delivery and release within
174 corporation of FC5 as the BBB-carrier arm in bispecific antibodies or antibody-drug conjugates offers
176 We describe the application of a novel, bispecific antibody platform termed dual affinity retarg
178 e dramatically improved therapeutic index of bispecific antibody pretargeting appears to be sufficien
183 ability, enabling efficient knobs-into-holes bispecific antibody production and a robust path to gene
189 an affinity-enhancement system consisting of bispecific antibodies separating targeting from delivery
191 ing distinct facets of fracture healing, the bispecific antibody shows superior bone repair activity
192 ites, we have focused on the construction of bispecific antibodies specific for the tumor antigen HER
194 s and yields milligram to gram quantities of bispecific antibodies sufficient for a wide range of dis
195 e have applied this technology to generate a bispecific antibody suitable for development as a human
197 port our work expanding the knobs-into-holes bispecific antibody technology to the human IgG4 isotype
198 state cancer using an anti-TROP-2 x anti-HSG bispecific antibody (TF12) in conjunction with the dual-
202 gammadelta T-cell cytotoxicity, we designed bispecific antibodies that bind CD3 or Vgamma9 on gammad
203 g sites, such as epratuzumab and HU1D10, and bispecific antibodies that can directly interact with ce
204 latform for the mammalian cell production of bispecific antibodies that differ from their parental mA
205 odies that utilize a common light chain, and bispecific antibodies that pair light chains to their co
206 With this approach, we generated potent bispecific antibodies that recruit cytotoxic T lymphocyt
209 antibody constructs including one-armed Abs, bispecific antibodies that utilize a common light chain,
211 eloid-Specific TNF Inhibitor)--a recombinant bispecific antibody that binds to the F4/80 surface mole
212 the technology with an example of a CD3/CD20 bispecific antibody that effectively depletes B cells in
214 rmined whether therapeutic responses using a bispecific antibody that pretargeted (90)Y-hapten-peptid
217 tibodies enables the clinical application of bispecific antibodies to a validated therapeutic pathway
218 ted in the scientific literature that extend bispecific antibodies to other human antibody isotypes.
220 racer in situ by pretargeting a multivalent, bispecific antibody to carcinoembryonic antigen (CEA), w
222 domain of human tissue factor, by means of a bispecific antibody, to an experimentally induced marker
224 e, we describe a new approach for generating bispecific antibodies using a common light chain format
227 ons triggered by XGFR, the Fc portion of the bispecific antibody was glycoengineered, which resulted
232 sing T-cell engaging immunotherapies such as bispecific antibodies which target T cells and tumor cel
233 apid generation and chemical optimization of bispecific antibodies, which are termed bispecific CovX-
235 ology to develop a heterodimeric OAscFab-IgG bispecific antibody, which combines potent signaling inh
236 proach, we synthesized an anti-HER2/anti-CD3 bispecific antibody, which efficiently cross-linked HER2
237 des additional options for the generation of bispecific antibodies with differing effector functions
238 t of patients with malignant gliomas, and of bispecific antibodies with hapten-radionuclides in the t
239 broadens the range of published therapeutic bispecific antibodies with natural surface architecture
240 e efficient heterodimerization, resulting in bispecific antibodies with physiochemical properties ver
243 ases bone mass, we engineer a first-in-class bispecific antibody with single residue pair mutations i
245 ultaneous targeting of both receptors with a bispecific antibody would lead to enhanced antitumor act
247 owever, most approaches utilized to generate bispecific antibodies yield antibody-like structures tha
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。